Prospective non-blinded examination by comparing bone PET with F-18 NaF and conventional bone scintigraphy

Prospective non-blinded examination by comparing bone PET with F-18 NaF and conventional bone scintigraphy - Prospective non-blinded examination by comparing bone PET with F-18 NaF and conventional bone scintigraphy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027684

Enrollment

Registered

2017-06-08

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone disease

Interventions

Between the approval of the Ethics Committee of Osaka City University Medical School Hospital and March 31, 2019, 40 patients with bone disease who underwent bone scintigraphy receive 185 MBq of F-18

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients planning to perform bone scintigraphy in bone disease

Exclusion criteria

Exclusion criteria: 1) Patients with a history of allergy to the study drug 2) During pregnancy or suspected women, lactating women 3) Patients who received other test drugs or test drugs within 3 months prior to the start of administration of study drug 4) Patients judged by the investigator as inappropriate as subjects

Design outcomes

Primary

Measure	Time frame
We evaluate the usefulness of the quantitative diagnostic ability of bone PET by comparing the quantitative evaluation of lesions in bone PET and bone scintigraphy performed almost at the same time.	—

Countries

Japan

Contacts

Public ContactJoji Kawabe, M.D.,Ph.D.

Graduate school of medicine, Osaka city university Department of Nuclear medicine

asahimachinm@gmail.com06-6645-3885

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026